Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Prepaid Assets (2020 - 2025)

Historic Prepaid Assets for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $1.8 million.

  • SAB Biotherapeutics' Prepaid Assets fell 996.33% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 996.33%. This contributed to the annual value of $3.0 million for FY2024, which is 2716.02% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Prepaid Assets of $1.8 million as of Q3 2025, which was down 996.33% from $3.6 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Prepaid Assets high stood at $3.6 million for Q2 2025, and its period low was $102742.0 during Q3 2021.
  • Over the past 5 years, SAB Biotherapeutics' median Prepaid Assets value was $1.8 million (recorded in 2025), while the average stood at $1.8 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Prepaid Assets surged by 103855.89% in 2022 and then plummeted by 5956.8% in 2023.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Prepaid Assets stood at $2.6 million in 2021, then plummeted by 43.33% to $1.5 million in 2022, then soared by 56.68% to $2.3 million in 2023, then grew by 27.16% to $3.0 million in 2024, then tumbled by 38.31% to $1.8 million in 2025.
  • Its Prepaid Assets stands at $1.8 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.4 million for Q1 2025.